Geron

Geron Corp. operates as a biotechnology company. It develops a telomerase inhibitor, Imetelstat, in hematologic myeloid malignancies. The firm develops therapeutic products for oncology. The company was founded by Michael D. West on November 28, 1990 and is headquartered in Foster City, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Geron reports positive trial results and financial strength for growth

Geron's Q4 2022 earnings call showcases promising developments in clinical trials and strategic commercialization plans. While facing increased expenses and challenges in trial enrollment and regulatory processes, the company remains well-positioned with a solid financial foundation and opportunities for growth.

Geron reports strong Q1 performance, eyes global expansion opportunities

Geron's Q1 performance reflects optimism around Imetelstat's potential in MDS and myelofibrosis treatment.
Strong financial resources and strategic market positioning provide a foundation for sales expansion and growth.
While challenges exist in pricing and market adoption, Geron is poised to capitalize on opportunities for global expansion.

Geron reports progress with imetelstat in lower-risk MDS

Geron's Q2 call highlighted imetelstat's potential in lower-risk MDS, with a focus on commercial readiness and financial updates. Challenges include addressing physician concerns and managing rising expenses.

Geron progresses towards FDA approval for imetelstat in 2024

Geron is on track for FDA approval of imetelstat in late 2024, supported by a robust financial position and strategic commercialization plans.
The company's focus on transfusion independence and positive market feedback highlight the potential market success of imetelstat.
Challenges in dosing, mutation efficacy, and partnership opportunities require careful navigation for successful market penetration.
Physician adoption and patient switching dynamics present opportunities for imetelstat to gain market share and establish itself as a valuable treatment option.

Geron poised for FDA approval of imetelstat, eyes $7B market

Geron's Q4 2023 earnings call highlighted strong financials, positive trial results for imetelstat, and upcoming regulatory milestones in 2024. While facing challenges related to safety assessments and physician education, the company is well-positioned to capitalize on the substantial market opportunity for imetelstat.

Geron poised for U.S. launch of imetelstat with FDA support

Geron's strong financial position and FDA support bode well for the potential approval and successful U.S. launch of imetelstat. While facing challenges in clinical development timelines and patent decisions, the company is poised to address unmet needs and create commercial value. Opportunities in new markets and extended exclusivity offer avenues for growth and market positioning.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that it will release its first quarter 2023 financial results on Thursday, May 11, 2023 at 8:00 a.m. Eastern Time via press release, which will be available on the Company's website at www.geron.com/investors. Geron will host a conference call to discuss the financial results, as well as business highlights and upcoming milestones, at 10:30 a.m. Eastern Time t.

Geron to Announce First Quarter 2023 Financial Results on May 11, 2023

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that data from the pivotal IMerge Phase 3 clinical trial evaluating the Company's first-in-class telomerase inhibitor, imetelstat, in lower risk myelodysplastic syndromes (MDS), was accepted for oral presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting. The data in the ASCO abstract will be embargoed per ASCO guidelines until Ma.

Geron Announces Upcoming Oral Presentation at 2023 American Society of Clinical Oncology Annual Meeting of Imetelstat Data from IMerge Phase 3 Lower Risk MDS Trial

Geron's imetelstat has shown promise to treat a rare blood disorder. The drug could have wide oncology applications.

Why Shares of Geron Are Up 30% This Week

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that John A. Scarlett, M.D., Geron's Chairman and Chief Executive Officer, is scheduled to participate in fireside chats at following investor conferences: 22nd Annual Needham Virtual Healthcare Conference Thursday, April 20 at 10:15 a.m. ET Stifel 2023 Virtual Targeted Oncology Days Tuesday, April 25 at 2:00 p.m.

Geron to Present at Upcoming Investor Conferences in April

Geron Corporation (NASDAQ:GERN ) Q4 2022 Earnings Conference Call March 16, 2023 4:30 PM ET Company Participants Aron Feingold - Vice President, Investor Relations and Corporate Communications John Scarlett - Chairman and Chief Executive Officer Olivia Bloom - Executive Vice President and Chief Financial Officer Faye Feller - Executive Vice President and Chief Medical Officer Anil Kapur - Executive Vice President, Corporate Strategy and Chief Commercial Officer Conference Call Participants Kalpit Patel - B. Riley Stephen Willey - Stifel Joel Beatty - Baird Gil Blum - Needham Operator Good afternoon.

Geron Corporation (GERN) Q4 2022 Earnings Call Transcript

Geron (GERN) delivered earnings and revenue surprises of 9.09% and 11.21%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Geron (GERN) Reports Q4 Loss, Misses Revenue Estimates

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company developing a first-in-class telomerase inhibitor, imetelstat, to treat hematologic malignancies, today reported business updates, upcoming milestones and financial results for the fourth quarter and year ended December 31, 2022.

Geron Corporation Reports Fourth Quarter and Full Year 2022 Financial Results and Upcoming Milestones

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that it will release its fourth quarter and full-year 2022 financial results after the market closes on Thursday, March 16, 2023 via press release, which will be available on the Company's website at www.geron.com/investors. Geron will host a conference call to discuss the financial results as well as upcoming milestones at 4:30 p.m. ET the same day.

Geron to Announce Fourth Quarter and Full-Year 2022 Financial Results on March 16, 2023

Geron recently raised funds, but its stock did not go down. This was because of the excellent IMERGE data.

Geron's Commercial Plans Are Taking Shape

Eos Energy Enterprises

Inozyme Pharma, Inc.

Use these tips for trading penny stocks in the short term The post Choosing Penny Stocks for Short Term Trading; 3 Tips appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Choosing Penny Stocks for Short Term Trading; 3 Tips

Aligos Therapeutics

Apexigen Inc

Ardelyx

Analysts have put these on their list of penny stocks to buy. Do you agree?

4 Penny Stocks To Buy According To Analysts & Targets Over 600%

FOSTER CITY, Calif.--( BUSINESS WIRE )--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that John A. Scarlett, M.D., Geron's Chairman and Chief Executive Officer, is scheduled to participate in a virtual fireside chat at the B. Riley Securities 3rd Annual Virtual Oncology Conference on January 18 at 1 p.m. ET.

Geron to Present at the B. Riley Securities 3rd Annual Virtual Oncology Conference

FOSTER CITY, Calif.--( BUSINESS WIRE )--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today highlighted multiple additions to its senior commercial leadership team, as it prepares for the potential commercialization in the U.S. market of imetelstat, a first-in-class telomerase inhibitor. Key additions include seasoned professionals with deep operational and launch experience in Trade & Channel Relations, Market Access, Marketing, Medical Affairs and Sales. The Company recently reported positive top-line results from its IMerge Phase 3 clinical trial in lower risk myelodysplastic syndromes (MDS) and is planning a New Drug Application (NDA) submission in the U.S. in mid-2023 and a Marketing Authorization Application (MAA) submission in the EU in the second half of 2023.

Geron Announces Experienced Commercial Leadership Hired for Planned Commercial Launch of Imetelstat in the U.S.

FOSTER CITY, Calif.--( BUSINESS WIRE )--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced the closing of its upsized underwritten public offering of common stock and pre-funded warrants, plus the full exercise of the underwriters' option to purchase additional shares of common stock for total gross proceeds of $227.8 million. All of the securities in the offering were sold by Geron.

Geron Corporation Announces Closing of Upsized Public Offering of Common Stock and Pre-Funded Warrants Plus Full Exercise of the Underwriters' Option to Purchase Additional Shares for Total Gross Proceeds of $227.8 Million

Primary endpoint of 8-week transfusion independence met in the phase 3 IMerge study; Imetelstat was used as a monotherapy to treat patients with lower-risk myelodysplastic syndrome. Regulatory applications in the U.S. and Europe, of imetelstat for lower-risk myelodysplastic syndrome, are expected in 2023.

Geron's Data Allows Development Of Several Catalysts

CytomX Therapeutics

Zomedica

Are you using these tips for investing in penny stocks? The post How to Start Investing in Penny Stocks in 2023 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

How to Start Investing in Penny Stocks in 2023

FOSTER CITY, Calif.--( BUSINESS WIRE )--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced the pricing of an upsized underwritten public offering consisting of 55,876,297 shares of its common stock at a public offering price of $2.45 per share and pre-funded warrants to purchase 25,000,000 shares of its common stock. The pre-funded warrants are being sold at a public offering price of $2.449 per pre-funded warrant. All of the securities in the offering are to be sold by Geron. In addition, Geron has granted the underwriters a 30-day option to purchase up to an additional 12,131,444 shares of its common stock, less underwriting discounts and commissions. The offering is expected to close on or about January 10, 2023, subject to the satisfaction of customary closing conditions.

Geron Corporation Announces Pricing of $198 Million Upsized Public Offering of Common Stock and Pre-Funded Warrants

Geron (GERN) posts positive top-line data from the phase III IMerge study investigating its lead candidate, imetelstat for treating lower risk myelodysplastic syndromes. Shares up.

Geron (GERN) Up on Imetelstat Data on Myelodysplastic Syndromes

SoFi Technologies

Vivos Therapeutics

Here's why penny stocks climb in price The post What Makes Penny Stocks Move? 3 Major Factors to Consider appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

What Makes Penny Stocks Move? 3 Major Factors to Consider

FOSTER CITY, Calif.--( BUSINESS WIRE )--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that it intends to offer and sell $175 million of shares of its common stock in an underwritten public offering. All of the securities in the proposed offering are to be sold by Geron. Geron intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the number of shares of its common stock offered in the public offering. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Geron Corporation Announces Proposed Public Offering of Common Stock

2022 was a terrible year for us biotech investors. We wanted 2023 to be good, and one of the most difficult stocks out there, Geron Corporation, has paid off today.

Geron: The First Success Story Of The New Year

Though the major indices posted a strong recovery effort on Wednesday, late-stage clinical biopharmaceutical firm Geron (NASDAQ: GERN ) soared above most public players. Following positive top-line results for its blood cancer therapeutic, GERN stock jumped 50% before settling around 34% up in the early afternoon.

Why Is Geron (GERN) Stock Soaring 50% Today?

Vera Therapeutics

The binary nature of biotech investing is making itself obvious from recent study results.

These 2 Nasdaq Biotechs Are Making Big Moves Wednesday

FOSTER CITY, Calif.--( BUSINESS WIRE )--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced positive top-line results from its IMerge Phase 3 clinical trial evaluating the Company's first-in-class telomerase inhibitor, imetelstat, in lower risk myelodysplastic syndromes (MDS) patients who are relapsed, refractory or ineligible for erythropoiesis stimulating agents (ESAs). The trial met its primary efficacy endpoint of 8-week TI and a key secondary endpoint of 24-week TI, demonstrating highly statistically significant and clinically meaningful benefit of imetelstat versus placebo with no new safety signals and safety results consistent with prior imetelstat clinical trials.

Geron Announces Positive Top-Line Results from IMerge Phase 3 Trial of Imetelstat in Lower Risk MDS

FOSTER CITY, Calif.--( BUSINESS WIRE )--Geron Corporation (Nasdaq: GERN) today announced that it will host a conference call to discuss top-line results from the IMerge Phase 3 clinical trial of imetelstat, the Company's first-in-class telomerase inhibitor, in lower risk myelodysplastic syndromes (MDS) on January 4, 2023, at 8:00 a.m. ET.

News for Geron Stock (GERN)